Sleep Cycle Salute del bilancio
Criteri Salute finanziaria verificati 6/6
Sleep Cycle ha un patrimonio netto totale di SEK71.8M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK200.1M e SEK128.3M. L'EBIT di Sleep Cycle è SEK65.7M rendendo il suo rapporto di copertura degli interessi -56.9. Ha liquidità e investimenti a breve termine pari a SEK120.8M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
SEK 0
Debito
| Indice di copertura degli interessi | -56.9x |
| Contanti | SEK 120.85m |
| Patrimonio netto | SEK 71.83m |
| Totale passività | SEK 128.32m |
| Totale attività | SEK 200.15m |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery
Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential
Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside
Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside
Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside
Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts
Feb 09
Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53
Feb 07
SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play
Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside
Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside
Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings
Jan 04SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential
Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 09Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.
Aug 27
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
Apr 30The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%
Apr 29Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
Apr 08
Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships
Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's
Mar 06Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year
Feb 10Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model
Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device forAnalisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( SEK176.0M ) di SLEEP superano le sue passività a breve termine ( SEK124.1M ).
Passività a lungo termine: Le attività a breve termine di SLEEP ( SEK176.0M ) superano le sue passività a lungo termine ( SEK4.2M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: SLEEP è esente da debiti.
Riduzione del debito: SLEEP non ha avuto debiti negli ultimi 5 anni.
Copertura del debito: SLEEP non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.
Copertura degli interessi: SLEEP non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.
Bilancio
Scoprire le aziende sane
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/30 06:30 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sleep Cycle AB (publ) è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Oscar Erixon | Carnegie Investment Bank AB |
| Erik Granström | DNB Carnegie |
| Rikard Engberg | DNB Carnegie Commissioned Research |